Education Academy Logo
Journal Logo

Conference Abstracts - 2026 National Summit on Hematologic Cancers

Vol. 6, Issue Supplement 2, 2026 · S1-2

Impact of Supplemental Prebiotics on Patients Undergoing Chimeric Antigen Receptor Therapy (CAR T) Cell Therapy with Ciltacabtagene Autoleucel for Multiple Myeloma – Phase I Study

Indumathy Varadarajan, MBBS,Krishna Gandhi, MD

CARVYKTIPre bioticsPhase I study

Submission received: 2026-08-14 / Accepted: 2026-08-25 / Published: 2026-09-28

CCBY-SA-4.0
Publication: IJCCDhttps://doi.org/10.53876/001a.129819
0

Abstract

Background

Studies show that the success and side effects of CAR T-cell therapy are linked to the gut microbiome's diversity and metabolite production. A healthy, non-disrupted gut microbiome is associated with a better response to CAR T-cell therapy and lower toxicity. Ciltacabtagene Autoleucel is a B cell maturation antigen (BCMA)-targeting CAR-T therapy that is highly effective in relapsed refractory myeloma. Although Ciltacel is associated with a 70% complete response, it has 10% non-relapse mortality and delayed neurotoxicity. 75% of patients experience cytokine release syndrome (CRS) and 14% experience neurological toxicity (ICANS). Hence, preemptive interventions are needed to reduce toxicity.

Methods

We propose a phase I study of feasibility and tolerance in patients undergoing CAR-T cell therapy with Ciltacel, using a commercially available prebiotic supplement to be taken twice a day starting 1 week prior to Lymphodepleting chemotherapy to Day +100 after CAR-T cell therapy. Primary outcomes: compliance will be defined as the ability to consume the supplement > 80% of days. Secondary objectives – Incidence of Grade 3, 4 CRS, Grade 3,4 ICANS, and Delayed Neurotoxicity, 1 yr PFS and 1 yr OS. Exploratory objectives – 16s RNA sequencing of stool sample Day -5 and then once every 4 weeks until Day +100. CART cell expansion and persistence assay starting from Day +7 to Day +100.

Results

Impact of Study: Studies have not looked into modulating the gut microbiome to improve CAR-T outcomes in human recipients. Therefore, investigating prebiotics in CAR T-cell therapy would be highly impactful because it offers a safe, accessible, and non-infectious strategy to proactively modulate the gut microbiome. Prebiotic supplementation could fundamentally shift CAR T-cell treatment protocols. Rather than managing toxicities like ICANS reactively with immunosuppressants, this intervention could simultaneously enhance the antitumor potency of CAR T-cells, improving survival and quality of life for patients.

Conclusion

We would like to submit this proposal for the Impact Pitch as the trial is currently being designed.